Skip to content
Company Analysis

Vivos Therapeutics, Inc. VVOS

A comprehensive view of key metrics, scores, and financial health for Vivos Therapeutics, Inc.

Overview of Vivos Therapeutics, Inc.

VVOS NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Vivos Therapeutics, Inc. (VVOS), is a Micro Cap company, in the Medical Devices industry, last closed at $0.11, about 0.0% overvalued vs fair value, -95.3% 1Y return, ranked 791/1145 in sector.
Metrics Rev Growth 16.1% ROE -656.9% Gross Margin 60.4%
USD 0.11
-5.26%
(Delayed)
• Vol 90d: 99.1%
Market Cap
$2.18M
Enterprise Value
$9.48M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 90%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.vivos.com
HQ Littleton, CO
Employees 262
Fiscal year Dec 31

Next Events

Earnings Nov 16 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $0.11

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$17.4M
16%%
Gross Profit
$10.5M
16.9%%
Operating Income (GAAP)
-$19.9M
-78.1%%
EBITDA
-$18.6M
-75.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
60.4%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Vivos Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
31
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Durable Revenue Growth Revenue growth trend is strong (score 0.67). Durable top-line expansion confirms the razor-and-blade flywheel is working.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.06). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.32). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
46
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 68% Coverage
Trade-Off Triangle Visualization A ternary plot showing VVOS's balance between Growth (51.7%), Profitability (27.4%), and Safety (21.0%). Growth 52% Safety 21% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

55th percentile vs peers
55
Key Signals
Rev Growth YoY 16.1% 69p Revenue CAGR 3Y 2.9% 41p EPS Growth YoY 6.9% 38p Asset Growth YoY 64.6% 92p
Strengths

No notable strengths identified for this axis.

Risks

No significant risks identified for this axis.

Profitability

29th percentile vs peers
29
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

22th percentile vs peers
22
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Vivos Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.24
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000